Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

 
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
 

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
 
How to report

You can send the case reports using the following tools:
 
  1. For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
 
  1. The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones
 
  1. Scan the QR Code by pressing the link
  2. Click the three dots in the top-right corner
  3. Choose Install app
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app
 
How to Download on Apple IOS Phones
 
  1. Scan the QR Code by pressing the link
  2. Click on the share button
  3. Add VigiMobile to the home screen
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows
  1. Press on the link
  2. Install from the Browser menu
  3. VigiMobile e-Form/e-Reporting e-Form is now installed 
 
Scan QR Codes to Report:
  1. ADRs Following Medication Use
  1. AEFIs Following Vaccine Use
Or use the following link: LNPVP: e-Reporting eForm Or use the following link: LNPVP: VigiMobile eForm
 
  1. Direct Contact with the Lebanese National Pharmacovigilance Program:
You may contact the Lebanese National Pharmacovigilance Program through:
  • Email Address:
  • Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254   
 
  1.  For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.
 
As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-
 
    ...
    6
ATC Name B/G Ingredients Dosage Form Price
G03XC01 RALOXIFENE ARROW G Raloxifene HCl - 60mg 60mg Tablet, coated 1,425,817 L.L
M01AC02 REUTENOX G Tenoxicam - 20mg 20mg Tablet, coated 576,508 L.L
N05AX08 RISPERIDONE BIOGARAN G Risperidone - 1mg 1mg Tablet, coated, scored 643,701 L.L
N05AX08 RISPERIDONE BIOGARAN G Risperidone - 2mg 2mg Tablet, coated, scored 1,488,977 L.L
N05AX08 RISPERIDONE BIOGARAN G Risperidone - 4mg 4mg Tablet, coated, scored 1,105,982 L.L
M01AB05 ROFENAC D G Diclofenac free acid - 50mg 50mg Tablet, dispersible 408,528 L.L
A11GA01 REDOXON EFF.ORANGE B Ascorbic acid (vit C) - 1g 1g Tablet, effervescent 366,869 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 727,019 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 1,252,461 L.L
A02BC02 RAZON 20 G Pantoprazole (sodium) - 20mg 20mg Tablet, enteric coated 747,176 L.L
A02BC04 RABEZOL 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 282,847 L.L
A02BC04 RABEZOL 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 639,925 L.L
A02BC04 RAZOLE 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 282,847 L.L
A02BC04 RAZOLE 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 639,925 L.L
N05AH04 REZAL XR G Quetiapine fumarate - 200mg 200mg Tablet, extended release 2,116,552 L.L
N05AH04 REZAL XR G Quetiapine fumarate - 300mg 300mg Tablet, extended release 2,535,831 L.L
N05AH04 REZAL XR G Quetiapine fumarate - 50mg 50mg Tablet, extended release 533,505 L.L
B01AF01 RIBAVAN G Rivaroxaban - 20mg 20mg Tablet, film coated 1,343,843 L.L
R06AX27 RINA 5 G Desloratadine - 5mg 0.5mg/ml Tablet, film coated 134,384 L.L
B01AF01 RIXALTA 20 G Rivaroxaban - 20mg 20mg Tablet, film coated 1,164,664 L.L
B01AF01 RIBAVAN G Rivaroxaban - 10mg 10mg Tablet, film coated 959,888 L.L
B01AF01 RIXALTA 10 G Rivaroxaban - 10mg 10mg Tablet, film coated 671,921 L.L
A06AX05 RESOLOR B Prucalopride succinate - 2mg 2mg Tablet, film coated 5,251,736 L.L
A06AX05 RESOLOR B Prucalopride succinate - 1mg 1mg Tablet, film coated 3,273,600 L.L
M01AE51 RELI-FLU G Ibuprofen - 200mg, Pseudoephedrine HCl - 30mg Tablet, film coated 139,504 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 487,623 L.L
C10AA07 ROSUPHAR G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 487,623 L.L
C10AA07 ROSUVAS G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 450,187 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 720,525 L.L
    ...
    6
Sitemap
© Copyrights reserved to Ministry of Public Health 2025